Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Physiotherapy Intervention Program for Chronic Pain Associated With Depressive Disorder

17 août 2026 mis à jour par: Sandra Calvo Carrión, Instituto de Investigación Sanitaria Aragón

Effects of a Hybrid Physiotherapy Program Based on Pain Neuroscience Education and Therapeutic Exercise in Individuals With Chronic Persistent Pain and Depressive Disorder: A Prospective Longitudinal Study

This prospective longitudinal pre-post intervention study aims to evaluate the effects of an 8-week physiotherapy program combining face-to-face and asynchronous tele-rehabilitation sessions in individuals with chronic persistent pain and depressive disorder. The intervention is based on pain neuroscience education and therapeutic exercise. Outcomes include pain intensity, psychosocial factors, adherence to treatment, usability of telemedicine, balance, body awareness, and participants' experiences collected through focus groups.

Aperçu de l'étude

Statut

Complété

Intervention / Traitement

Type d'étude

Interventionnel

Inscription (Réel)

34

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Zaragoza, Espagne
        • Zaragoza University and San Jorge University

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Oui

La description

Inclusion Criteria:

  • Age 45-75 years
  • User of AFDA and ASAPME
  • Chronic persistent pain
  • Written informed consent provided

Exclusion Criteria:

  • Severe psychiatric disorders (including schizophrenia)
  • Neurological diseases preventing participation
  • No internet access
  • Mini-Mental State Examination score ≤24
  • Acute musculoskeletal disorders
  • Rheumatic diseases
  • Severe respiratory insufficiency
  • Inability to understand Spanish
  • Pregnancy, immunosuppression, transplantation or active oncological condition

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Hybrid Physiotherapy Program
Hybrid Physiotherapy Program consisted of Pain Neuroscience Education and Therapeutic Exercise

Hybrid Physiotherapy Program consisted of Pain Neuroscience Education and Therapeutic Exercise:

Behavioral: Pain Neuroscience Education Eight weekly face-to-face educational sessions complemented by asynchronous telematic educational videos covering pain neurophysiology, biopsychosocial approaches, neuroplasticity, motor imagery and self-management strategies.

Behavioral: Therapeutic Exercise Eight weeks of supervised group exercise. Exercises include strength, aerobic, balance, flexibility, coordination and dual-task activities.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Pain Intensity (Numering Rating Scale)
Délai: Baseline and Week 8
It is a numerical scale ranging from 1 to 10, where 1 represents the absence of pain and 10 represents the highest intensity.
Baseline and Week 8

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Pain Catastrophizing Scale
Délai: Baseline and Week 8
This scale indicates the extent to which each of the 13 thoughts described is experienced. They are rated on a Likert scale ranging from 0 ('never') to 4 ('always'). The total score is calculated, with 52 being the maximum score. Low scores indicate low levels of catastrophising, whilst high scores indicate high levels of catastrophising.
Baseline and Week 8
Chronic Pain Coping Questionnaire
Délai: Baseline and Week 8
The scale assesses the way in which patients cope with pain. It comprises six factors to be measured: religion, catharsis, distraction, mental self-control, self-affirmation and information-seeking. Within each factor there are between 5 and 6 items scored on a scale of 0 to 4, where 0 means 'strongly disagree' and 4 means 'strongly agree'. Greater use of active strategies such as distraction, self-affirmation or seeking information is associated with better emotional adjustment. Taken together, the score obtained provides an insight into how pain is coped with.
Baseline and Week 8
Tampa Scale for Kinesiophobia (TSK-11)
Délai: Baseline and Week 8
11-item self-report questionnaire that assesses perceptions of frailty and the tendency to avoid movement for fear of injury or increased pain. Each item is scored on a 4-point scale (1: strongly disagree; 4: strongly agree). A high score on the TSK-11 indicates a greater fear of movement, a greater perception of physical frailty and a more pronounced tendency to avoid activities for fear of pain or injury. Conversely, low scores reflect lower kinesiophobia and a more confident attitude towards movement.
Baseline and Week 8
Chronic Pain Self-Efficacy Questionnaire
Délai: Baseline and Week 8
This questionnaire consists of 19 items designed to assess the patient's confidence in their own ability to carry out various activities and manage the consequences of persistent pain. The scale is divided into three main domains or subscales: self-efficacy for pain control, for physical function and for symptom management. Each item is rated on a scale ranging from 0 ('completely unable') to 10 ('completely able'). A high score on this scale indicates a greater perceived ability to manage pain, maintain activity and manage symptoms, whilst low scores reflect lower confidence, greater dependence and poorer coping.
Baseline and Week 8
Depression Anxiety Stress Scale (DASS-21)
Délai: Baseline and Week 8
The DASS-21 scale measures patients' emotional state and is used to assess three distinct areas: depression, anxiety and stress. This scale consists of 21 questions divided into three groups of seven items each. For each question, the patient must assign a score from 0 to 3, where 0 means that 'nothing has happened' and 3 means that 'it has happened a lot or most of the time'. Once completed, the points for each section (depression, anxiety and stress) are added together and the result is multiplied by 2 to obtain the final score for each category. Higher scores on each subscale indicate a greater presence of symptoms of depression, anxiety or stress, whilst lower scores reflect a better emotional state.
Baseline and Week 8
Fear Avoidance Beliefs Questionnaire (FABQ)
Délai: Baseline and Week 8
This scale is based on patients' beliefs about how their pain affects their physical activity and work. This questionnaire consists of 16 items, of which 5 relate to beliefs regarding physical activity (FABQ-PA) - these are the items we will be assessing. Each item is rated on a Likert scale from 0 to 6, where 0 means 'strongly disagree' and 6 means 'strongly agree'. High scores indicate a high level of beliefs that lead to avoidance of activity.
Baseline and Week 8
Clinical Global Impression Scale (CGI)
Délai: Baseline and Week 8
This scale assesses two aspects: the severity of the illness prior to treatment and the overall improvement following the intervention. It is a Likert-type scale ranging from 0 to 7. To assess the severity of the illness, 0 corresponds to 'not assessed' and 1 to 'normal, not ill', progressing up to 7, which represents 'among the most severely ill patients'. As regards overall improvement, 0 corresponds to 'not assessed', 1 to 'much better' and 7 to 'much worse'. It is a useful tool for assessing severity and response to treatment due to its practicality and clinical validity.
Baseline and Week 8
Qualitative outcomes from focus groups
Délai: Week 8
The focus-group sessions will be transcribed verbatim in full by a single researcher from the audio recordings. The transcripts will then be coded inductively and analysed independently by the research team. The analysis will begin at the most descriptive level, identifying units of meaning, which will be grouped into thematic codes-clusters of units of meaning referring to the same content, and progressively organised into categories, themes, and sub-themes until the main themes emerge. Beyond this descriptive coding, the analysis will move to an interpretive, inferential level, in which the team draws inferences about the meaning of the emerging themes rather than merely describing them. As this qualitative strand forms part of a mixed-methods design, these qualitative inferences will subsequently be integrated with the quantitative findings to generate meta-inferences, so that each strand informs and contextualises the other.
Week 8

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Collaborateurs

Les enquêteurs

  • Chercheur principal: Sandra S Calvo, Phd, University Zaragoza
  • Chercheur principal: Carolina C Jiménez-Sánchez, Phd, San Jorge University

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

5 février 2024

Achèvement primaire (Réel)

30 mai 2026

Achèvement de l'étude (Réel)

30 mai 2026

Dates d'inscription aux études

Première soumission

10 août 2026

Première soumission répondant aux critères de contrôle qualité

10 août 2026

Première publication (Réel)

14 août 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

19 août 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

17 août 2026

Dernière vérification

1 août 2026

Plus d'information

Termes liés à cette étude

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner